Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic
Lead candidate demonstrates specificity, biologic activity and a favorable safety profile in extensive mouse and non-human primate models Upcoming company presentations at Cellicon Valley ’23 and In Vivo Engineering of Therapeutic Cells Summit PHILADELPHIA, June 21, 2023 /PRNewswire/ — Interius BioTherapeutics, a leading developer of in vivo cell-specific genetic medicine therapeutics, today announced the presentation of compelling … Read more